Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

[New support services for the care of young patients with rheumatic diseases].

Schalm S, Niewerth M, Minden K.

Z Rheumatol. 2018 Oct;77(8):685-693. doi: 10.1007/s00393-018-0547-x. Review. German.

PMID:
30251111
2.

The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry.

Girschick H, Finetti M, Orlando F, Schalm S, Insalaco A, Ganser G, Nielsen S, Herlin T, Koné-Paut I, Martino S, Cattalini M, Anton J, Mohammed Al-Mayouf S, Hofer M, Quartier P, Boros C, Kuemmerle-Deschner J, Pires Marafon D, Alessio M, Schwarz T, Ruperto N, Martini A, Jansson A, Gattorno M; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever registry.

Rheumatology (Oxford). 2018 Aug 1;57(8):1504. doi: 10.1093/rheumatology/key143. No abstract available.

PMID:
29718410
3.

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.

J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.

4.

The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry.

Girschick H, Finetti M, Orlando F, Schalm S, Insalaco A, Ganser G, Nielsen S, Herlin T, Koné-Paut I, Martino S, Cattalini M, Anton J, Al-Mayouf SM, Hofer M, Quartier P, Boros C, Kuemmerle-Deschner J, Pires Marafon D, Alessio M, Schwarz T, Ruperto N, Martini A, Jansson A, Gattorno M; PRINTO and the Eurofever registry.

Rheumatology (Oxford). 2018 Mar 27. doi: 10.1093/rheumatology/key058. [Epub ahead of print] Erratum in: Rheumatology (Oxford). 2018 Aug 1;57(8):1504.

PMID:
29596638
5.

Building a transitional care checklist in rheumatology: A Delphi-like survey.

Akre C, Suris JC, Belot A, Couret M, Dang TT, Duquesne A, Fonjallaz B, Georgin-Lavialle S, Larbre JP, Mattar J, Meynard A, Schalm S, Hofer M.

Joint Bone Spine. 2018 Jul;85(4):435-440. doi: 10.1016/j.jbspin.2017.09.003. Epub 2017 Sep 28.

PMID:
28965941
6.

EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases.

Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S, Berggren K, van Pelt P, Wouters C, Waite-Jones J, Tattersall R, Wyllie R, Stones SR, Martini A, Constantin T, Schalm S, Fidanci B, Erer B, Demirkaya E, Ozen S, Carmona L.

Ann Rheum Dis. 2017 Apr;76(4):639-646. doi: 10.1136/annrheumdis-2016-210112. Epub 2016 Nov 1. Erratum in: Ann Rheum Dis. 2018 Jun;77(6):960.

7.

[Transition from pediatric to adult rheumatological care].

Minden K, Schalm S.

Z Rheumatol. 2016 Aug;75(6):635-45. doi: 10.1007/s00393-016-0140-0. Review. German.

PMID:
27444620
8.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, Yang H, Travins J, Murray S, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, Liu W, Yen KE.

Blood. 2015 Jan 8;125(2):296-303. doi: 10.1182/blood-2013-10-533604. Epub 2014 Nov 14.

9.

The landscape of kinase fusions in cancer.

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C.

Nat Commun. 2014 Sep 10;5:4846. doi: 10.1038/ncomms5846.

10.

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE.

Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.

11.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK.

Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

12.

[Transitional care in rheumatology in Germany].

Schalm S, Jansson AF.

Internist (Berl). 2012 Sep;53(9):1054-62. doi: 10.1007/s00108-012-3027-4. German.

PMID:
22941457
13.

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.

Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C.

Eur J Health Econ. 2012 Oct;13(5):663-76. doi: 10.1007/s10198-012-0413-8. Epub 2012 Jul 20.

14.

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, Harris IS, Holmes R, Wakeham A, Haight J, You-Ten A, Li WY, Schalm S, Su SM, Virtanen C, Reifenberger G, Ohashi PS, Barber DL, Figueroa ME, Melnick A, Zúñiga-Pflücker JC, Mak TW.

Nature. 2012 Aug 30;488(7413):656-9. doi: 10.1038/nature11323.

15.

Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.

Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ; DITTO-HCV Study Group.

BMC Gastroenterol. 2012 Jan 31;12:11. doi: 10.1186/1471-230X-12-11.

16.

Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review.

Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C.

BMC Infect Dis. 2011 Dec 12;11:337. doi: 10.1186/1471-2334-11-337. Review.

17.

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.

Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group.

Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3.

PMID:
21389795
18.

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M.

J Hepatol. 2011 Nov;55(5):980-8. doi: 10.1016/j.jhep.2011.01.050. Epub 2011 Feb 25.

PMID:
21354446
19.

Proteolytic processing of protocadherin proteins requires endocytosis.

Buchanan SM, Schalm SS, Maniatis T.

Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17774-9. doi: 10.1073/pnas.1013105107. Epub 2010 Sep 27.

20.

Phosphorylation of protocadherin proteins by the receptor tyrosine kinase Ret.

Schalm SS, Ballif BA, Buchanan SM, Phillips GR, Maniatis T.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13894-9. doi: 10.1073/pnas.1007182107. Epub 2010 Jun 25.

21.

[Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].

Sauvain MJ, Schalm SB, Bérthet G, Bolz D, Cannizzaro E, Hofer M, Kaiser D, Saurenmann RK, Bolt IB.

Praxis (Bern 1994). 2010 May 26;99(11):649-54. doi: 10.1024/1661-8157/a000144. German.

PMID:
20506089
22.

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups.

Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509.

PMID:
20186843
23.

Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.

Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH.

Gastroenterology. 2010 Feb;138(2):522-30. doi: 10.1053/j.gastro.2009.10.039. Epub 2009 Oct 29.

PMID:
19879275
24.

Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.

Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky JM, Schalm SW, Ferrari C, Zeuzem S, Neumann AU; DITTO-HCV Study Group.

J Viral Hepat. 2010 May;17(5):345-51. doi: 10.1111/j.1365-2893.2009.01183.x. Epub 2009 Sep 25.

PMID:
19780947
25.

Clinical use of interferon in hepatitis B and C.

Schalm SW.

Verh K Acad Geneeskd Belg. 2009;71(1-2):87-99. Review.

PMID:
19739400
26.

Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.

Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW.

Hepatology. 2009 Sep;50(3):743-51. doi: 10.1002/hep.23061.

PMID:
19585616
27.

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.

Buster EH, Schalm SW, Janssen HL.

Best Pract Res Clin Gastroenterol. 2008;22(6):1093-108. doi: 10.1016/j.bpg.2008.11.007. Review.

PMID:
19187869
28.
30.

High impact of migration on the prevalence of chronic hepatitis B in the Netherlands.

Marschall T, Kretzschmar M, Mangen MJ, Schalm S.

Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1214-25. doi: 10.1097/MEG.0b013e32830e289e.

PMID:
18946359
31.

A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.

Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M; DITTO-HCV Study Group.

Scand J Gastroenterol. 2008 Jan;43(1):73-80.

PMID:
18938750
32.

Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

de Bruijne J, Buster EH, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW, Bakker CM, Zaaijer HL, Janssen HL, Reesink HW; Netherlands Association of Gastroenterologists and Hepatologists.

Neth J Med. 2008 Jul-Aug;66(7):311-22. Review. Erratum in: Neth J Med. 2008 Dec;66(11):456. Dosage error in article text.

33.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists.

Neth J Med. 2008 Jul-Aug;66(7):292-306. Review.

34.

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.

Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):773-7. doi: 10.1097/MEG.0b013e3282f793d6.

PMID:
18617782
35.

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.

Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

Hepatology. 2008 Jun;47(6):1856-62. doi: 10.1002/hep.22251.

PMID:
18506898
36.

Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.

Pugnale P, Herrmann E, Neumann AU, Pawlotsky JM, Schalm SW, Ferrari C, Homburger Y, Zeuzem S, Negro F; DITTO-HCV Study Group.

J Hepatol. 2008 Jun;48(6):932-8. doi: 10.1016/j.jhep.2008.02.018. Epub 2008 Mar 31.

PMID:
18433918
37.

Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.

Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M.

Eur J Gastroenterol Hepatol. 2008 Apr;20(4):320-6. doi: 10.1097/MEG.0b013e3282f340c8. Review.

PMID:
18334876
38.

Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.

ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van' t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV 99-01 Study Group.

Antivir Ther. 2007;12(8):1285-94.

PMID:
18240868
39.

Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.

van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC.

Nephrol Dial Transplant. 2008 Feb;23(2):721-5. Epub 2007 Nov 27.

PMID:
18042614
40.

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

Ann Intern Med. 2007 Nov 20;147(10):677-84.

PMID:
18025443
41.

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G; DITTO-HCV Study Group.

Gastroenterology. 2007 Oct;133(4):1132-43. Epub 2007 Jul 3.

PMID:
17919489
42.

Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.

Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A, de Vries RA, Verhey E, Hansen BE, Brouwer JT, Janssen HL, Schalm SW, de Knegt RJ.

Liver Int. 2007 Nov;27(9):1217-25.

PMID:
17919233
43.

In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.

Sprengers D, van der Molen RG, Binda R, Kusters JG, de Man RA, Niesters HG, Schalm SW, Janssen HL.

J Viral Hepat. 2007 Oct;14(10):743-9.

PMID:
17875010
44.

Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.

Flink HJ, Buster EH, Merican I, Nevens F, Kitis G, Cianciara J, de Vries RA, Hansen BE, Schalm SW, Janssen HL.

Gut. 2007 Oct;56(10):1485-6. No abstract available.

45.

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Hepatology. 2007 Aug;46(2):388-94.

PMID:
17604363
46.

Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.

Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV.

J Med Virol. 2007 Aug;79(8):1055-63.

PMID:
17596838
47.

Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.

Westin J, Hellstrand K, Alsiö A, Ydreborg M, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Verhey-Hart E, Lagging M.

Hepatology. 2007 May;45(5):1333-4; author reply 1334. No abstract available.

PMID:
17464982
48.
49.

Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.

Veldt BJ, Schalm SW, Janssen HL.

J Clin Gastroenterol. 2007 Apr;41(4):432. No abstract available.

PMID:
17413616
50.

[Changes in the management of patients with side effects from the treatment of hepatitis C].

Bezemer G, Schalm SW, van Gool AR, de Knegt RJ.

Ned Tijdschr Geneeskd. 2007 Mar 3;151(9):525-30. Review. Dutch.

PMID:
17373393

Supplemental Content

Loading ...
Support Center